Identity
- Trade Name
- LIAISON® Progesterone II Gen FDA UDI
- Generic Name
- Progesterone IVD, kit, chemiluminescent immunoassay FDA UDI
- Model / Reference
- 310690 FDA UDI
Identifiers
- Primary DI / UDI-DI
- 08056771600217 FDA UDI
- GMDN Term
- Progesterone IVD, kit, chemiluminescent immunoassay FDA UDI
Classification
- Commercial Distribution
- In Commercial Distribution FDA UDI
Clinical & Handling
Sterile
No
FDA UDI
Single Use
No
FDA UDI
Implantable
No
FDA UDI
Contains Latex
No
FDA UDI
Prescription Use
No
FDA UDI
Over-the-Counter
No
FDA UDI
Convenience Kit
Yes
FDA UDI
Combination Product
No
FDA UDI
HCT/P
No
FDA UDI
Premarket Exempt
No
FDA UDI
Lot / Batch Number
Yes
FDA UDI
Serial Number
No
FDA UDI
Expiration Date
Yes
FDA UDI
Manufacturing Date
No
FDA UDI
Category: Progesterone IVD, kit, chemiluminescent immunoassay
LIAISON® Progesterone II Gen by Diasorin Inc. — FDA UDI — listed in FDA GUDID — regulatory data on deviCERTS
Similar devices
Also classified as Progesterone IVD, kit, chemiluminescent immunoassay.
- Progesterone (serum) — DRG International, Inc. · Class I
- Dimension Vista® Flex® reagent cartridge PROG — Siemens Healthcare Diagnostics · Class I
- VITROS — Ortho-Clinical Diagnostics · Class I
- IMMULITE® 2000 Systems PRG Progesterone — SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS LTD · Class I
- Progesterone Luminescence Immunoassay — IBL International GmbH · Class I
- Progesterone AccuLite CLIA Test System - 192 Wells — MONOBIND, INC. · Class I
- Alinity — ABBOTT IRELAND · Class I
- Elecsys Progesterone III — Roche Diagnostics Corp. · Class I
Authorization Coverage (1 country)
Regulatory Authorizations
United States Pending data
FDA UDI
| Source | Region | Type | Cert / Approval No. | Class | Status |
|---|---|---|---|---|---|
| FDA UDI | United States | FDA UDI | Registered in GUDID | N/A | Pending data |
Is this your device? Claim it to add documentation and request validation.
Manufacturer
- Manufacturer
- Diasorin Inc.
Sources (1)
- FDA UDI 07d3fb87-1998-453f-b306-437c61a0bdde 33 fields · synced May 30, 2026